MIST News and Press, Milestone Pharmaceuticals Inc. From 11/10/22

Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update Canada NewsWire - Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat dose ...

Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022 Canada NewsWire Trial met its primary endpoint, with 64.3% of patients receiving etri...

Summary Etripamil succeeded in phase 3 RAPID study, Milestone in talks with FDA to possibly file an NDA for this drug in treating PSVT patients by mid-2023. It is said that there are about 2 million PSVT patients in the United States currently. Etripamil is being explored in a...

Summary Milestone Pharmaceuticals reported positive data from the RAPID arm of its pivotal trial. After an initial premarket spurt, the stock dropped drastically. Since I cannot find a plausible negative reason, I think this makes the stock attractive. I covered Mile...

Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022 Canada NewsWire MONTREA...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com It’s time to start off the trading week with a breakdown of the biggest pre-market stock movers on Monday! Moving stocks this morning is a $16.5 million case reward, clini...

Milestone Pharmaceuticals ( NASDAQ: MIST ), a company focused on cardiovascular medicines, announced Monday that its lead asset, etripamil reached the primary endpoint in a Phase 3 trial for patients with the heart condition paroxysmal supraventricular tachycardia (PSVT). MIST s...

Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia Canada NewsWire ─     Trial met its primary endpoint, with 64.3% of patient...

Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C. , Sept. 6, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company foc...

Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q2 GAAP EPS of -$0.39 misses by $0.03 . cash, cash equivalents, and short-term investments of $86.2 million For further details see: Milestone Pharmaceuticals GAAP EPS of -$0.39 misses by $0.03